ArticleCancer research2019
Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 85 papers.
0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed
13.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 140 citations in OpenAlex.
- Association between concomitant ACEI/ARBs use and survival of patients with prostate cancer receiving abiraterone acetate: A post-hoc analysis of two randomized trials.Prostate cancer and prostatic diseases · 2026Observational
- Non-metastatic castration-resistant prostate cancer in the epoch of PSMA-ligand PET/CT: twilight?Annals of nuclear medicine · 2026Review
- Decoding the Raf-Mek-Erk-Rsk pathway in prostate cancer: from molecular mechanisms to clinical opportunities.British journal of cancer · 2026Review
- ECM (collagen) mediated signaling drives the emergence of androgen independence in prostate cancer cells.Biochemistry and biophysics reports · 2026Article
- AURKA inhibitor VIC-1911 induces mitotic defects and functional BRCAness, sensitizing prostate cancer to PARP inhibition.JCI insight · 2026Article
- Molecular mechanisms and classification of castration-resistant prostate cancer: Insights into androgen receptor, cancer stem cells, and neuroendocrine features.Current urology · 2026Article
- Magnocurarine inhibits migration and invasion by suppressing mesenchymal marker expression and MAPK signaling in castration-resistant prostate cancer cells.Frontiers in pharmacology · 2026Article
- Targeting RPS6KC1 to overcome enzalutamide resistance in prostate cancer.Biomarker research · 2025Article
- Cholesterol metabolism regulated by CAMKK2-CREB signaling promotes castration-resistant prostate cancer.Cell reports · 2025Article
- ADT increases prostate cancer cell invasion via altering AR/SALL4/SOX2-OCT4 stem cell signaling.Cell biology and toxicology · 2025Article
- FMNL2/SRC-mediated androgen receptor translocation into the nucleus promotes enzalutamide resistance of prostate cancer.iScience · 2025Article
- Integrated proteogenomic characterization of localized prostate cancer identifies biological insights and subtype-specific therapeutic strategies.Nature communications · 2025Article
- Dynamic molecular atlas of cardiac fibrosis at single-cell resolution shows CD248 in cardiac fibroblasts orchestrates interactions with immune cells.Nature cardiovascular research · 2025Article
- Therapeutic targeting of Aurora Kinase A in advanced prostate cancer.Serican journal of medicine · 2025Article
- G protein-coupled receptors in prostate cancer: research progress and therapeutic targets.Frontiers in cell and developmental biology · 2025Review
- Osteoblast-Derived ECM1 Promotes Anti-Androgen Resistance in Bone Metastatic Prostate Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Prp19/CDC5L promotes gastric cancer via activation of the MAPK pathway-mediated homologous recombination.International journal of biological sciences · 2025Article
- Targeting mRNA-coding genes in prostate cancer using CRISPR/Cas9 technology with a special focus on androgen receptor signaling.Cell communication and signaling : CCS · 2024Review
- Bioinformatics analysis reveals that CBX2 promotes enzalutamide resistance in prostate cancer.European journal of medical research · 2024Article
- LncRNA LOC730101 Promotes Darolutamide Resistance in Prostate Cancer by Suppressing miR-1-3p.Cancers · 2024Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
17 authors at 7 institutions in 3 countries.
Shangze Li *Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.ORCID 0000-0003-3134-532X
Ka-Wing Fong *Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Galina GritsinaDivision of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Ali ZhangDivision of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Jonathan C ZhaoDivision of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Jung KimDivision of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Adam SharpInstitute of Cancer Research, London, United Kingdom.
Wei YuanInstitute of Cancer Research, London, United Kingdom.
Caterina AversaInstitute of Cancer Research, London, United Kingdom.
Ximing J YangDepartment of Pathology, Northwestern University, Chicago, Illinois.
Peter S NelsonDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Felix Y FengDepartments of Radiation Oncology, Urology, and Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Arul M ChinnaiyanMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Johann S de BonoInstitute of Cancer Research, London, United Kingdom.
Colm MorrisseyDepartment of Urology, University of Washington, Seattle, Washington.
Matthew B RettigDepartment of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California.
Jindan YuDivision of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois. jindan-yu@northwestern.edu.
Northwestern University · USInstitute of Cancer Research · GBFred Hutch Cancer Center · USMichigan Center for Translational Pathology · USUCSF Helen Diller Family Comprehensive Cancer Center · USUniversity of California, Los Angeles · USUniversity of Washington · US
Funding
TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI John Kyung Lee · 2002 to 2026
$58.1MTargeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancerP50CA180995 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ABDULKADIR, SARKI A., HUSSAIN, MAHA H · 2015 to 2025
$19.9MCARCINOGENESIS TRAINING PROGRAMT32CA009560 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Kathleen Janee Green · 1986 to 2026
$8.4MTRAINING IN METABOLISM, DIABETES AND ENDOCRINOLOGYT32DK007169 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Joseph Bass · 1988 to 2026
$6.6MThe Role of NOV (CCN3) in Prostate Cancer ProgressionR01CA172384 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI YU, JINDAN · 2013 to 2017
$1.6MGenomics and bioinformatics analysis to understand castration-resistant prostate cancerR50CA211271 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ZHAO, CHANGSHENG · 2016 to 2020
$701kDepartment of HealthMedical Research Council MR/M018318/1NCI NIH HHS P50 CA097186NCI NIH HHS P50 CA180995NCI NIH HHS R01 CA172384NCI NIH HHS R50 CA211271NCI NIH HHS T32 CA009560NIDDK NIH HHS T32 DK007169
Abstract
Castration-resistant prostate cancer (CRPC) that has developed resistance to the new-generation androgen receptor (AR) antagonist enzalutamide is a lethal disease. Transcriptome analysis of multiple prostate cancer models identified CXCR7, an atypical chemokine receptor, as one of the most upregulated genes in enzalutamide-resistant cells. AR directly repressed
Indexed as
Drug Resistance, NeoplasmMAP Kinase Signaling SystemAnimalsAntineoplastic AgentsBenzamidesCell DivisionCell Line, TumorCell SurvivalHEK293 CellsHumansMaleMiceMice, Inbred BALB CMice, NudeNeoplasm InvasivenessNitrilesACKR3 protein, humanAntineoplastic AgentsBenzamidesenzalutamideNitrilesPhenylthiohydantoinPyridonesPyrimidinonesReceptors, CXCRtrametinib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.